<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097158</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#5190061</org_study_id>
    <nct_id>NCT04097158</nct_id>
  </id_info>
  <brief_title>Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone</brief_title>
  <official_title>Oxidative Markers and Efficacy in Amyotrophic Lateral Sclerosis (ALS) Phenotypes Treated With Edaravone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to help the investigators better understand how the new FDA
      approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS.
      The investigators are also trying to understand if there are specific ALS patients, with
      different presentations of ALS, who might benefit most from this medication. Also, the
      investigators are following specific biomarkers to determine the optimal treatment duration
      in patients with different forms of ALS

      There is no study medication being offered in this trial. Edaravone is prescribed as part of
      regular care. In this trial we are collecting blood, urine, and spinal fluid samples in ALS
      patients who are taking Edaravone and ALS patients who are not taking Edaravone to measure
      certain markers that could indicate why the drug may be working in a specific type of ALS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Define pharmacodynamic biomarkers of oxidative stress and antioxidant capacity in different ALS/MND phenotypes.</measure>
    <time_frame>6 months</time_frame>
    <description>The investigators aim to identify 4 cohorts of patients with distinct ALS/MND phenotypes and measure a panel of pharmacodynamic biomarkers of oxidative stress and antioxidant capacity in the CSF, blood, and urine.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Upper Motor Neuron predominant ALS</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower Motor Neuron predominant ALS</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Bulbar predominant ALS</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Generalized ALS</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sample Collection</intervention_name>
    <description>The investigators will be collecting blood, urine, and spinal fluid samples.</description>
    <arm_group_label>Bulbar predominant ALS</arm_group_label>
    <arm_group_label>Generalized ALS</arm_group_label>
    <arm_group_label>Lower Motor Neuron predominant ALS</arm_group_label>
    <arm_group_label>Upper Motor Neuron predominant ALS</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Spinal Fluid Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Anyone who meets the Inclusion/Exclusion Criteria
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Either possible, probable, or definite ALS, predominantly lower motor neuron disease,
             predominantly upper motor neuron disease, or bulbar

          2. With or without cognitive involvement

          3. Willing to participate

          4. On no experimental treatment

          5. Ages 18 - 85

          6. No prior exposure to Edaravone (Radicava)

          7. On a stable dose of Riluzole for 30 days or off Riluzole

          8. Male or female

          9. Females of childbearing age must use contraception

        Exclusion Criteria:

          1. Unstable medical illness

          2. Abnormal liver function (&gt;2x ULN)

          3. Unlikely to survive for 26 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Rosenfeld, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Imran Qasim</last_name>
    <phone>(909) 558-2037</phone>
    <phone_ext>25388</phone_ext>
    <email>sqasim@llu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imran Qasim</last_name>
      <phone>909-558-2037</phone>
      <phone_ext>25388</phone_ext>
      <email>sqasim@llu.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Rosenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Jeffrey Rosenfeld</investigator_full_name>
    <investigator_title>Director, Neuromuscular ALS/MND Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

